Cost analysis of risk-stratified screening based on FIT results Skip to content The CRC Digest Cost analysis of risk-stratified screening based on FIT results Real-world data examined resource use and costs of a low-risk screening approach for people with previous negative fecal immunochemical tests. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always
Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark Skip to content The CRC Digest Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark A study from the Danish Polyposis Register emphasizes the importance of lifelong endoscopic surveillance and tailored treatment strategies for FAP patients, who face elevated risks for duodenal and pancreatic cancers even after colectomy. (APMIS) This
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers Skip to content The CRC Digest Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy.
Blood-Based Screening Biomarkers Under Review Skip to content The CRC Digest Blood-Based Screening Biomarkers Under Review Researchers identified novel blood test candidates that could complement or enhance current colorectal cancer screening approaches. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The